Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.

[1]  Catherine Caillet,et al.  Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease. , 2015, Bioorganic & medicinal chemistry letters.

[2]  A. Azvolinsky.  Industry chases pan-genotypic and shorter HCV treatments , 2015, Nature Biotechnology.

[3]  B. Beno,et al.  A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. , 2015, Journal of medicinal chemistry.

[4]  Catherine Caillet,et al.  Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease. , 2014, Bioorganic & medicinal chemistry letters.

[5]  Catherine Caillet,et al.  Development of Related HCV Protease Inhibitors: Macrocyclization of Two Highly Functionalized Dienyl-ureas via Ring-Closing Metathesis , 2013 .

[6]  Zhilei Chen,et al.  Probing the Role of Sigma π Interaction and Energetics in the Catalytic Efficiency of Endo-1,4-β-Xylanase , 2012, Applied and Environmental Microbiology.

[7]  S. Zeuzem,et al.  Telaprevir for the treatment of hepatitis C , 2012, Expert opinion on pharmacotherapy.

[8]  F. Penin,et al.  Nonstructural protein 3‐4A: the Swiss army knife of hepatitis C virus , 2011, Journal of viral hepatitis.

[9]  O. Hucke,et al.  Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335* , 2011, The Journal of Biological Chemistry.

[10]  Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. , 2010, Reviews on recent clinical trials.

[11]  J. Timm,et al.  Serine protease inhibitors as anti-hepatitis C virus agents , 2009, Expert review of anti-infective therapy.

[12]  Weiliang Zhu,et al.  Halogen bonding--a novel interaction for rational drug design? , 2009, Journal of medicinal chemistry.

[13]  Elizabeth Hamelink,et al.  Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. , 2008, Bioorganic & medicinal chemistry letters.

[14]  Yoshihisa Inoue,et al.  Propensities of polar and aromatic amino acids in noncanonical interactions: nonbonded contacts analysis of protein-ligand complexes in crystal structures. , 2007, Journal of medicinal chemistry.

[15]  Z. Zhan,et al.  Development of New Ruthenium Catalysts for Metathesis Reactions , 2008 .

[16]  J. Hoofnagle,et al.  Peginterferon and ribavirin for chronic hepatitis C. , 2006, The New England journal of medicine.

[17]  Y. Takeda,et al.  Liver transplantation for hepatitis C. , 2006, Journal of hepato-biliary-pancreatic surgery.

[18]  A. Hallberg,et al.  Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3. , 2006, Bioorganic & medicinal chemistry.

[19]  Dennis G. Gillingham,et al.  Ru complexes bearing bidentate carbenes: from innocent curiosity to uniquely effective catalysts for olefin metathesis. , 2004, Organic & biomolecular chemistry.

[20]  M. Poirier,et al.  A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors. , 2004, Journal of medicinal chemistry.

[21]  X. Forns,et al.  Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. , 2004, Gastroenterology.

[22]  Martin Poirier,et al.  Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position. , 2004, Journal of medicinal chemistry.

[23]  P. Bonneau,et al.  Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. , 2003, Angewandte Chemie.

[24]  Bruce E. Smart,et al.  Fluorine substituent effects (on bioactivity) , 2001 .

[25]  Gleiter,et al.  Long-range sigma-pi interactions in tetrahydro-4H-thiopyran end-capped oligo(cyclohexylidenes). Photo-electron spectroscopy, ab initio SCF MO calculations, and natural bond orbital analyses , 2000, The Journal of organic chemistry.

[26]  D. Lamarre,et al.  Peptide-based inhibitors of the hepatitis C virus serine protease. , 1998, Bioorganic & medicinal chemistry letters.

[27]  C. Yoakim,et al.  Pharmacokinetic aspects of palinavir, an HIV protease inhibitor, in Sprague-Dawley rats. , 1998, Journal of pharmaceutical sciences.

[28]  L. Tong,et al.  Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere. , 1997, Journal of medicinal chemistry.